Medipharm Book Value Per Share vs Price To Sales Ratio Analysis

LABS Stock

CAD 0.07 0.01 7.14%

Medipharm Labs financial indicator trend analysis is infinitely more than just investigating Medipharm Labs Corp recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Medipharm Labs Corp is a good investment. Please check the relationship between Medipharm Labs Book Value Per Share and its Price To Sales Ratio accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medipharm Labs Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Book Value Per Share vs Price To Sales Ratio

Book Value Per Share vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Medipharm Labs Corp Book Value Per Share account and Price To Sales Ratio. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Medipharm Labs' Book Value Per Share and Price To Sales Ratio is -0.63. Overlapping area represents the amount of variation of Book Value Per Share that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Medipharm Labs Corp, assuming nothing else is changed. The correlation between historical values of Medipharm Labs' Book Value Per Share and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Book Value Per Share of Medipharm Labs Corp are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Book Value Per Share i.e., Medipharm Labs' Book Value Per Share and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

-0.63

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Medipharm Labs Corp stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Medipharm Labs sales, a figure that is much harder to manipulate than other Medipharm Labs Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most indicators from Medipharm Labs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Medipharm Labs Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medipharm Labs Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

As of the 13th of December 2024, Selling General Administrative is likely to drop to about 14.7 M. In addition to that, Tax Provision is likely to grow to about (262.2 K)

	2021	2022	2023	2024 (projected)
Cost Of Revenue	37.0M	24.0M	28.8M	35.0M
Research Development	1.4M	1.0M	209K	198.6K

Cost Of Revenue Research Development

Medipharm Labs fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant And Equipment Net	Non Current Assets Total	Other Assets	Common Stock Total Equity	Short Term Investments	Other Current Assets	Net Invested Capital	Long Term Investments	Cash And Equivalents
Total Assets		0.72	0.92	0.95	0.99	0.95	-0.75	-0.49	0.85	0.94	0.94	0.63	0.77	0.92	1.0	0.52	0.78	0.99	0.99	0.93	0.82	0.75	0.76	1.0	0.49	0.92
Short Long Term Debt Total	0.72		0.78	0.85	0.63	0.55	-0.1	-0.07	0.65	0.47	0.47	0.17	0.57	0.92	0.71	0.85	0.36	0.71	0.72	0.73	0.42	0.77	0.61	0.69	0.85	0.44
Other Current Liab	0.92	0.78		0.89	0.9	0.91	-0.61	-0.6	0.64	0.84	0.84	0.68	0.65	0.9	0.91	0.6	0.83	0.95	0.94	0.78	0.88	0.83	0.91	0.92	0.45	0.86
Total Current Liabilities	0.95	0.85	0.89		0.91	0.86	-0.54	-0.37	0.88	0.81	0.81	0.53	0.65	0.98	0.94	0.73	0.65	0.94	0.95	0.95	0.71	0.71	0.66	0.93	0.62	0.79
Total Stockholder Equity	0.99	0.63	0.9	0.91		0.96	-0.83	-0.53	0.83	0.97	0.97	0.66	0.77	0.86	0.99	0.43	0.81	0.98	0.98	0.91	0.84	0.72	0.75	0.99	0.4	0.96
Net Tangible Assets	0.95	0.55	0.91	0.86	0.96		-0.84	-0.67	0.74	0.96	0.96	0.77	0.64	0.79	0.93	0.39	0.91	0.96	0.95	0.85	0.9	0.67	0.77	0.95	0.26	0.98
Net Debt	-0.75	-0.1	-0.61	-0.54	-0.83	-0.84		0.67	-0.55	-0.92	-0.92	-0.75	-0.62	-0.44	-0.76	0.03	-0.84	-0.74	-0.72	-0.63	-0.79	-0.44	-0.57	-0.78	0.12	-0.92
Retained Earnings	-0.49	-0.07	-0.6	-0.37	-0.53	-0.67	0.67		-0.08	-0.63	-0.63	-0.97	-0.16	-0.3	-0.46	-0.21	-0.89	-0.58	-0.54	-0.24	-0.89	-0.44	-0.72	-0.52	0.42	-0.71
Accounts Payable	0.85	0.65	0.64	0.88	0.83	0.74	-0.55	-0.08		0.73	0.73	0.29	0.6	0.82	0.85	0.45	0.42	0.79	0.82	0.97	0.45	0.41	0.31	0.83	0.64	0.69
Cash	0.94	0.47	0.84	0.81	0.97	0.96	-0.92	-0.63	0.73		1.0	0.73	0.76	0.74	0.94	0.3	0.88	0.93	0.92	0.83	0.87	0.68	0.74	0.95	0.21	0.98
Cash And Short Term Investments	0.94	0.47	0.84	0.81	0.97	0.96	-0.92	-0.63	0.73	1.0		0.73	0.76	0.74	0.94	0.3	0.88	0.93	0.92	0.84	0.87	0.68	0.74	0.95	0.21	0.98
Common Stock Shares Outstanding	0.63	0.17	0.68	0.53	0.66	0.77	-0.75	-0.97	0.29	0.73	0.73		0.24	0.44	0.6	0.28	0.9	0.71	0.68	0.43	0.93	0.42	0.71	0.66	-0.3	0.81
Other Stockholder Equity	0.77	0.57	0.65	0.65	0.77	0.64	-0.62	-0.16	0.6	0.76	0.76	0.24		0.66	0.78	0.31	0.52	0.71	0.71	0.72	0.49	0.76	0.61	0.76	0.49	0.69
Total Liab	0.92	0.92	0.9	0.98	0.86	0.79	-0.44	-0.3	0.82	0.74	0.74	0.44	0.66		0.91	0.75	0.58	0.91	0.92	0.9	0.67	0.77	0.71	0.9	0.72	0.72
Total Current Assets	1.0	0.71	0.91	0.94	0.99	0.93	-0.76	-0.46	0.85	0.94	0.94	0.6	0.78	0.91		0.49	0.76	0.98	0.98	0.93	0.8	0.75	0.75	1.0	0.5	0.92
Short Term Debt	0.52	0.85	0.6	0.73	0.43	0.39	0.03	-0.21	0.45	0.3	0.3	0.28	0.31	0.75	0.49		0.33	0.56	0.56	0.55	0.37	0.62	0.48	0.49	0.55	0.31
Common Stock	0.78	0.36	0.83	0.65	0.81	0.91	-0.84	-0.89	0.42	0.88	0.88	0.9	0.52	0.58	0.76	0.33		0.83	0.8	0.59	0.95	0.68	0.84	0.8	-0.07	0.92
Property Plant And Equipment Net	0.99	0.71	0.95	0.94	0.98	0.96	-0.74	-0.58	0.79	0.93	0.93	0.71	0.71	0.91	0.98	0.56	0.83		1.0	0.9	0.87	0.75	0.81	0.99	0.42	0.94
Non Current Assets Total	0.99	0.72	0.94	0.95	0.98	0.95	-0.72	-0.54	0.82	0.92	0.92	0.68	0.71	0.92	0.98	0.56	0.8	1.0		0.92	0.85	0.72	0.77	0.99	0.45	0.93
Other Assets	0.93	0.73	0.78	0.95	0.91	0.85	-0.63	-0.24	0.97	0.83	0.84	0.43	0.72	0.9	0.93	0.55	0.59	0.9	0.92		0.6	0.59	0.5	0.92	0.61	0.8
Common Stock Total Equity	0.82	0.42	0.88	0.71	0.84	0.9	-0.79	-0.89	0.45	0.87	0.87	0.93	0.49	0.67	0.8	0.37	0.95	0.87	0.85	0.6		0.67	0.89	0.84	0.0	0.92
Short Term Investments	0.75	0.77	0.83	0.71	0.72	0.67	-0.44	-0.44	0.41	0.68	0.68	0.42	0.76	0.77	0.75	0.62	0.68	0.75	0.72	0.59	0.67		0.88	0.74	0.47	0.64
Other Current Assets	0.76	0.61	0.91	0.66	0.75	0.77	-0.57	-0.72	0.31	0.74	0.74	0.71	0.61	0.71	0.75	0.48	0.84	0.81	0.77	0.5	0.89	0.88		0.77	0.21	0.76
Net Invested Capital	1.0	0.69	0.92	0.93	0.99	0.95	-0.78	-0.52	0.83	0.95	0.95	0.66	0.76	0.9	1.0	0.49	0.8	0.99	0.99	0.92	0.84	0.74	0.77		0.44	0.94
Long Term Investments	0.49	0.85	0.45	0.62	0.4	0.26	0.12	0.42	0.64	0.21	0.21	-0.3	0.49	0.72	0.5	0.55	-0.07	0.42	0.45	0.61	0.0	0.47	0.21	0.44		0.14
Cash And Equivalents	0.92	0.44	0.86	0.79	0.96	0.98	-0.92	-0.71	0.69	0.98	0.98	0.81	0.69	0.72	0.92	0.31	0.92	0.94	0.93	0.8	0.92	0.64	0.76	0.94	0.14

Click cells to compare fundamentals

Medipharm Labs Account Relationship Matchups

Medipharm Labs fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	168.8M	118.2M	92.4M	65.5M	63.9M	75.9M
Short Long Term Debt Total	10.6M	18.5M	216K	632K	2.3M	2.2M
Other Current Liab	8.0M	10.0M	4.5M	4.0M	6.4M	4.6M
Total Current Liabilities	28.8M	24.2M	8.9M	9.5M	10.9M	13.7M
Total Stockholder Equity	131.5M	78.4M	83.1M	56.0M	53.0M	59.2M
Net Tangible Assets	27.6M	131.5M	78.2M	83.1M	95.6M	59.3M
Net Debt	(28.0M)	(1.5M)	(33.9M)	(23.5M)	(15.7M)	(16.5M)
Retained Earnings	(8.2M)	(74.5M)	(129.3M)	(163.6M)	(176.7M)	(167.9M)
Accounts Payable	19.1M	5.5M	3.0M	3.5M	2.1M	4.2M
Cash	38.6M	19.9M	34.1M	24.1M	18.0M	19.7M
Cash And Short Term Investments	38.6M	19.9M	34.1M	24.1M	18.0M	19.7M
Common Stock Shares Outstanding	134.6M	138.5M	249.9M	276.9M	363.3M	381.5M
Liabilities And Stockholders Equity	168.8M	118.2M	92.4M	65.5M	63.9M	75.9M
Other Stockholder Equity	976K	3.4M	16.9M	14.4M	21.9M	0.0
Total Liab	37.6M	39.8M	9.2M	9.5M	10.9M	17.1M
Total Current Assets	119.7M	81.5M	65.5M	47.3M	36.6M	52.0M
Accumulated Other Comprehensive Income	16.9M	14.4M	21.9M	28.4M	29.5M	15.8M
Short Term Debt	1.8M	7.7M	113K	598K	2.2M	2.7M
Common Stock	122.8M	138.5M	190.6M	191.3M	200.2M	120.7M
Property Plant And Equipment Net	42.2M	34.2M	25.9M	18.1M	25.3M	25.4M
Non Current Assets Total	49.1M	36.7M	26.8M	18.2M	27.3M	27.7M
Non Currrent Assets Other	6.1M	(52K)	876K	(18.2M)	1000.0K	1.0M
Other Assets	6.7M	2.1M	876K	0.0	1.0	0.95
Short Term Investments	679K	2.1M	1.1M	756K	265K	251.8K
Long Term Debt Total	8.8M	10.8M	103K	34K	39.1K	37.1K
Non Current Liabilities Total	8.8M	15.6M	338K	34K	69K	65.6K
Other Current Assets	2.0M	4.6M	3.1M	2.3M	2.9M	2.5M
Net Invested Capital	141.1M	96.3M	83.1M	56.5M	55.1M	73.3M
Cash And Equivalents	38.6M	19.9M	34.1M	24.1M	27.8M	22.9M
Net Working Capital	90.9M	57.3M	56.7M	37.9M	25.8M	44.1M
Property Plant Equipment	42.2M	34.1M	25.9M	18.1M	20.8M	25.0M
Net Receivables	27.5M	34.9M	17.4M	13.2M	5.9M	5.6M
Inventory	51.5M	22.1M	11.0M	7.8M	9.9M	14.9M
Property Plant And Equipment Gross	42.2M	34.1M	51.3M	43.2M	52.3M	43.5M
Capital Stock	122.8M	138.5M	190.6M	191.3M	200.2M	154.7M

Pair Trading with Medipharm Labs

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medipharm Labs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medipharm Labs will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Medipharm Labs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medipharm Labs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medipharm Labs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medipharm Labs Corp to buy it.

The correlation of Medipharm Labs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medipharm Labs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medipharm Labs Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Medipharm Labs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Medipharm Stock

Balance Sheet is a snapshot of the financial position of Medipharm Labs Corp at a specified time, usually calculated after every quarter, six months, or one year. Medipharm Labs Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Medipharm Labs and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Medipharm currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Medipharm Book Value Per Share vs Price To Sales Ratio Analysis

Book Value Per Share vs Price To Sales Ratio

Book Value Per Share vs Price To Sales Ratio Correlation Analysis

Correlation Coefficient

Book Value Per Share

Price To Sales Ratio

Medipharm Labs fundamental ratios Correlations

Medipharm Labs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Medipharm Labs fundamental ratios Accounts

Pair Trading with Medipharm Labs

Other Information on Investing in Medipharm Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Net Invested Capital	+ 1.0	Total Current Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Stockholder Equity	+ 0.99	Total Assets

Common Stock Shares Outstanding	- 0.97	Retained Earnings
Cash And Equivalents	- 0.92	Net Debt
Cash And Short Term Investments	- 0.92	Net Debt
Cash	- 0.92	Net Debt
Common Stock Total Equity	- 0.89	Retained Earnings
Common Stock	- 0.89	Retained Earnings